Discussion will focus on biotech investment trends – what has worked and is still working, availability of capital, the types of companies succeeding and lessons learned from those experiencing difficulties getting traction – along with an outlook for the year ahead. Our guest speakers from SVB Leerink represent the Investment Banking and Equity Capital Markets arenas and will provide invaluable insight on their outlook for biotech IPOs, crossovers, follow-ons and SPACs, as well as the deal environment for 2022.
AGENDA
Opening Remarks | Moderation
- Robert Uhl, Managing Director, Westwicke
- Patti Bank, Managing Director, Westwicke
Panelists
- Gabriel Cavazos, Senior Managing Director, Biotechnology, SVB Leerink
- Jack Bannister, Managing Director, Equity Capital Markets, SVB Leerink
